David R. Colnot

Phase I therapy study with (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and neck squamous cell carcinoma.

Pontus K.E. Börjesson, Ernst J. Postema, Jan C. Roos et al. · PubMed · 2003 · 114 citations

Pharmacy, Oncology, Radiation Oncology +17

Phase I therapy study of 186Re-labeled chimeric monoclonal antibody U36 in patients with squamous cell carcinoma of the head and neck.

David R. Colnot, Jasper J. Quak, Jan C. Roos et al. · PubMed · 2000 · 83 citations

Medicine, Nuclear Medicine, Oncology +17

Safety, biodistribution, pharmacokinetics, and immunogenicity of 99m Tc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck

David R. Colnot, Jan C. Roos, Remco de Bree et al. · Cancer Immunology Immunotherapy · 2003 · 70 citations · Full text

Pharmacy, Oncology, Pharmacokinetics +14

Clinical Significance of Micrometastatic Cells Detected by E48 (Ly-6D) Reverse Transcription-Polymerase Chain Reaction in Bone Marrow of Head and Neck Cancer Patients

David R. Colnot, Eline J. C. Nieuwenhuis, Dirk J. Kuik et al. · Clinical Cancer Research · 2004 · 51 citations · Full text

Medicine, Oncology, Pathology +13

Head and Neck Squamous Cell Carcinoma: US-guided Fine-Needle Aspiration of Sentinel Lymph Nodes for Improved Staging—Initial Experience

David R. Colnot, Eline J. C. Nieuwenhuis, Michiel W. M. van den Brekel et al. · Radiology · 2001 · 49 citations

Medicine, Oncology, Otolaryngology +17